PATENT CLAIM ANALYSIS

Application Number: 16105479
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "231500"]

Abstract:
Disclosed are methods for treating a meylodysplastic syndrome (MDS) in a subject that involves administering to the subject a therapeutically effective amount of a protein phosphatase 2A (PP2A) inhibitor.

Claim (Index 63):
The method of  claim 59 , wherein the MDS is characterized by refractory anemia (RA), refractory neutropenia (RN), refractory thrombocytopenia (RT), refractory anemia (RA) with ringed sideroblasts (RARS), refractory cytopenia with multilineage dysplasia (RCMD), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS), refractory anemia (RA) with excess blasts-1 (RAEB-1), refractory anemia (RA) with excess blasts-2 (RAEB-2) or refractory anemia (RA) with excess Blasts in Transformation (RAEB-t), or a combination thereof.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 96.0
- Lexical Diversity: 1.21429
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15328235', '15816372', '15048389', '14783360', '14408475']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.768462342130227
- 35 USC 102 Novelty (BERT): 0.6414140514068375
- Combined Prediction Score: 0.7557575130578881
- Mean Citation Score: 336.052712
- Max Citation Score: 643.62946
- Similarity Product: 544.8909438235677

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test